Free Trial

OncoCyte (OCX) Insider Trading & Ownership

OncoCyte logo
$2.19 -0.02 (-0.90%)
(As of 12/20/2024 05:16 PM ET)

OncoCyte (NASDAQ:OCX) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
1.58%
Number Of
Insiders Buying
(Last 12 Months)
5
Amount Of
Insider Buying
(Last 12 Months)
$11.20 M
Number Of
Insiders Selling
(Last 12 Months)
0
Get OCX Insider Trade Alerts

Want to know when executives and insiders are buying or selling OncoCyte stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

OCX Insider Buying and Selling by Quarter

OncoCyte Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/5/2024Andrea S JamesCFOBuy20,000$2.29$45,800.00  
10/2/2024Andrea S JamesCFOBuy33,670$2.97$99,999.90  
10/2/2024Broadwood Partners, L.P.Major ShareholderBuy1,315,339$2.95$3,880,250.05  
4/11/2024Andrew ArnoDirectorBuy33,898$2.95$99,999.10  
4/11/2024Broadwood Partners, L.P.Major ShareholderBuy2,420,000$2.92$7,066,400.00  
4/11/2024Josh RiggsCEOBuy3,390$2.95$10,000.50  
(Data available from 1/1/2013 forward)

OCX Insider Trading Activity - Frequently Asked Questions

The list of insiders at OncoCyte includes Alfred D Kingsley, Andrea S James, Andrew Arno, Andrew J Last, Broadwood Partners, L.P., Cavan M Redmond, Douglas T Ross, Gisela Paulsen, Josh Riggs, Li Yu, Pura Vida Investments, Llc, and Ronald Asbury Andrews. Learn more on insiders at OCX.

1.58% of OncoCyte stock is owned by insiders. Learn more on OCX's insider holdings.

The following insiders have purchased OCX shares in the last 24 months: Alfred D Kingsley ($13,300.00), Andrea S James ($145,799.90), Andrew Arno ($99,999.10), Broadwood Partners, L.P. ($18,994,936.05), Josh Riggs ($10,000.50), and Pura Vida Investments, Llc ($198,900.00).

Insiders have purchased a total of 5,203,578 OCX shares in the last 24 months for a total of $19,462,935.55 bought.

OncoCyte Key Executives

  • Mr. Joshua Riggs (Age 41)
    President, CEO & Director
    Compensation: $504.63k
  • Mr. James Liu (Age 28)
    Senior Director, Controller, Principal Accounting Officer & Interim Principal Financial Officer
    Compensation: $259.83k
  • Dr. Ekkehard Schutz M.D.
    Ph.D., Chief Science Officer
  • Mr. Peter Hong
    VP, General Counsel & Secretary
  • Mr. Yuh-Min Chiang Ph.D.
    Senior Vice President of R&D and Product Development
  • Ms. Sandra O'Donald
    Senior Vice President of Business Operations
  • Dr. Michael D. West Ph.D. (Age 71)
    Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc.


This page (NASDAQ:OCX) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners